4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Immunology by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 6373 ongoing clinical trials involving Immunology
Of the 6373 trials,1992 trials are in Phase III
Furthermore, 1923 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Immunology by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Immunology. The largest number of ongoing clinical trials for Immunology is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Immunology-related drug trials.

Johnson & Johnson: The leading ongoing Immunology related clinical trial sponsor

Johnson & Johnson is the top sponsor for Immunology-related ongoing clinical trials.

Bristol-Myers Squibb Co, Novartis AG, Assistance Publique - Hopitaux de Paris, and The National Institute of Allergy and Infectious Diseases are among other notable clinical trial sponsors involved in Immunology. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Immunology

Adalimumab (Humira), Ustekinumab (Stelara) and Etanercept (Enbrel, Enbrel PFS) are among the key marketed drugs involving Immunology.

Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). It functions via Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor mechanism of action. Adalimumab is formulated as injection for subcutaneous route of administration. Adalimumab was first approved in 2002 and is marketed globally in the US, Japan, the UK, China, Germany and France by several prominent pharma giants including AbbVie Inc.

Ustekinumab (Stelara) is a human monoclonal antibody used as immunosuppressant. It functions via Interleukin 12 Subunit Beta Inhibitor; Interleukin 23 Subunit Alpha Inhibitor mechanism of action. Ustekinumab is formulated as an injectable solution for injection, powder for solution and solution for injection in pre-filled syringe and is administered by subcutaneous route and intravenous administration and injectable concentrate solution for subcutaneous route of administration. Ustekinumab was first approved in 2008 and is marketed globally in the US, the UK, Australia, France and Germany by several prominent pharma giants including Janssen Biotech Inc.